Evidence map›Paper›PMID 35648199›Full record

ArticleWorld journal of urology2022

Neurogenic bladder in patients with paraplegia: a two-center study of the real-life experience of the patients' journey.

O Blé, J Levy, C Lefèvre, M A Perrouin-Verbe, A Even, L Le Normand, E Chartier Kastler, B Perrouin-Verbe, P Denys, C Joussain

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

O BléDepartment of Physical Medicine and Rehabilitation, Hospital Raymond-Poincaré AP-HP, Garches, France.
J LevyDepartment of Physical Medicine and Rehabilitation, Hospital Raymond-Poincaré AP-HP, Garches, France.
C LefèvreDepartment of Neurological Physical Medicine and Rehabilitation, Saint-Jacques Hospital, Nantes University Hospital, Nantes, France.
M A Perrouin-VerbeDepartment of Urology, Nantes University Hospital, Nantes, France.
A EvenDepartment of Physical Medicine and Rehabilitation, Hospital Raymond-Poincaré AP-HP, Garches, France.
L Le NormandDepartment of Urology, Nantes University Hospital, Nantes, France.
E Chartier KastlerPitié-Salpêtrière Academic Hospital, Department of Urology, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.
B Perrouin-VerbeDepartment of Neurological Physical Medicine and Rehabilitation, Saint-Jacques Hospital, Nantes University Hospital, Nantes, France.
P DenysDepartment of Physical Medicine and Rehabilitation, Hospital Raymond-Poincaré AP-HP, Garches, France.
C JoussainDepartment of Physical Medicine and Rehabilitation, Hospital Raymond-Poincaré AP-HP, Garches, France. charles.joussain@aphp.fr.ORCID http://orcid.org/0000-0002-5467-599X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSeveral patterns of urological dysfunctions have been described following spinal cord injury (SCI), depending on the level and the completeness of the injury. A better understanding of the natural history of neurogenic bladder in patients with SCI, and the description of their successive therapeutic lines based on their clinical and urodynamic pattern is needed to improve their management. This study aimed to describe the real-life successive therapeutic lines in patients with neurogenic lower urinary tract dysfunction (NLUTD) following SCI.

methodsWe conducted a two-center retrospective review of medical files of patients with SCI followed in two French specialized departments of Physical Medicine and Rehabilitation between January 2000 and January 2018. All patients with SCI with a level of lesion bellow T3 and older than 18 years old were eligible. The primary outcome was the description of the natural journey of neurogenic bladder in this population, from the awakening bladder contraction to the last therapeutic line. Survival curves were calculated with a 95-confidence interval using the Kaplan-Meier method.

resultsOne hundred and five patients were included in this study. Most of the patients were young men with a complete SCI lesion. The median time of treatment introduction was 1 and 9 years for anticholinergics and intradetrusor injection of BoNT/A, respectively. Median duration of effect of treatments was 4 and 6 years post-introduction of anticholinergics and BoNT/A, respectively.

conclusionThis study describes NLUTD journey of patients with SCI demonstrating the mid-term efficacy of the two first therapeutic lines of NDO management. An improvement of non-surgical therapeutics is needed.

Indexed as

Botulinum Toxins, Type ASpinal Cord InjuriesUrinary Bladder, NeurogenicUrinary Bladder, OveractiveAdolescentCholinergic AntagonistsHumansMaleParaplegiaUrodynamicsBotulinum Toxins, Type ACholinergic AntagonistsAnticholinergicBotulinum toxin ADrug therapy failureLong-termNeurogenic bladder

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.